# US 2024/0254078 A1 · Small molecule compounds having naphthylamine structure and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254078 A1
- Document ID: US20240254078A1
- Status: Published application
- Kind: A1
- Application number: 18/606,722
- Filed: 2024-03-15
- Published: 2024-08-01
- Earliest claimed: 0001-01-01
- Assignees: Hangzhou PhecdaMed Co., Ltd.
- Applicants: Hangzhou PhecdaMed Co., Ltd.
- Inventors: Hongguang XIA; Mengyang FAN; Xufeng CEN; Xiaoyan XU; Ronghai WU; Dong LIU; Zhen TIAN
- Web page: https://patentgrep.com/patent/US20240254078A1

## CPC

- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07C 311/21: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/381: having five-membered rings
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/402: 1-aryl substituted, e.g. piretanide
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/415: 1,2-Diazoles
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/42: Oxazoles
- A61K 31/433: Thidiazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61P 31/04: Antibacterial agents
- C07C 317/32: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 317/34: having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C 325/02: Thioketones; Oxides thereof
- C07D 207/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 213/71: to which a second hetero atom is attached
- C07D 231/18: One oxygen or sulfur atom
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 249/12: Oxygen or sulfur atoms
- C07D 257/04: Five-membered rings
- C07D 261/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 285/06: 1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C07D 285/10: 1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
- C07D 285/16: Thiadiazines; Hydrogenated thiadiazines
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 333/34: Sulfur atoms
- C07D 333/62: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07F 9/4476: {of aromatic amines (N-C aromatic linkage)}
- C07C 2601/02: with a three-membered ring
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present application discloses small molecule compounds having a naphthylamine structure and an application thereof. In the present application, the structure of a compound having a structure as shown in general formula (I) is as shown in the drawing. The compound and the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof that are provided by the present application or the pharmaceutical composition provided by the present application can selectively induce autophagy in damaged mitochondria without affecting or only weakly affecting normal mitochondria, and further have superior metabolic stability and pharmacokinetic properties, lower toxicity, and better druggability.

## Claims

### Claim 1

A compound having a structure represented by Formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof,
wherein:
Z is
R1 is hydrogen or C1˜6 alkyl;
R2 is hydrogen, C1˜6 alkyl, three to six-membered cycloalkyl, three to six-membered epoxyalkyl, phenyl or C1˜6 alkyl substituted phenyl;
R3 is
wherein R3-1 is hydrogen, hydroxyl, C1˜6 alkyl, C1˜6 alkoxy, three to six-membered cycloalkyl, three to six-membered epoxyalkyl, amino, C1˜6 amido, —CH2C(O)R3-2, —CH2C(O)OR3-2 or —CH2C(O)N(R3-2R3-2a),
R3-2 and R3-2a are each independently hydrogen, C1˜6 alkyl or three to six-membered cycloalkyl,
Ar is phenyl, naphthyl, 5- or 6-membered monocyclic heteroaryl, 8 to 10-membered fused bicyclic heteroaryl, phenyl with at least one hydrogen atom substituted by R3-3, naphthyl with at least one hydrogen atom substituted by R3-3, 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R3-3 or 8 to 10-membered fused bicyclic heteroaryl with at least one hydrogen atom substituted by R3-3, the R3-3 is hydrogen, halogen, C1˜6 alkyl, three to six-membered cycloalkyl, hydroxyl, C1˜6 alkoxy, three to six-membered epoxyalkyl, C1˜6 haloalkyl, C2˜6 alkenyl, C2˜6 alkynyl, —N(R3-3aR3-3b) or phenyl,
R3-3a and R3-3b are each independently hydrogen, C1˜6 alkyl or three to six-membered cycloalkyl;
R4 is
wherein R4-1 is phenyl, naphthyl, phenyl with at least one hydrogen atom substituted by R4-11, 5- or 6-membered monocyclic heteroaryl, 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R4-11 or 8 to 10-membered fused bicyclic heteroaryl, or 8- to 10-membered fused bicyclic heteroaryl with at least one hydrogen atom substituted by R4-11, and the R4-11 is hydrogen, halogen, nitro, nitrile group, hydroxyl, C1˜6 alkyl, three to six-membered cycloalkyl, C1˜6 alkoxy, —N(R4-1aR4-1b), phenyl, C1˜6 haloalkyl, C1˜6 haloalkoxy, —C(O)OR4-12, —C(O)R4-12, —C(O)N(R4-1aR4-1b), —S(O)2R4-12, —S(O)R4-12, —OC(O)R4-12, —OC(O)OR4-12 or
R4-12, R4-1a and R4-1b are each independently hydrogen, C1˜6 alkyl, three to six-membered cycloalkyl, C2˜6 alkenyl, C2˜6 alkynyl, C1˜6 alkyl with at least one hydrogen substituted by halogen, C2˜6 alkenyl with at least one hydrogen substituted by halogen, three to six-membered cycloalkyl with at least one hydrogen substituted by halogen, or C2˜6 alkynyl with at least one hydrogen substituted by halogen, and R4-1a and R4-1b can be bonded to each other to form a ring,
R4-2 is hydrogen, C1˜6 alkyl or three to six-membered cycloalkyl, or when R2 is C1˜6 alkyl, R4-2 and R2 are bonded to form a 4˜8 membered ring,
R4-3 is hydrogen, C1˜6 alkyl or C1˜6 alkoxy;
the number of R5 is 0˜5, and when the number of R5 is not 0, each R5 is independently selected from halogen, nitro, nitrile group, —N+(R5-1)3, C1˜6 haloalkyl, —C(O)OR5-1, —C(O)R5-1, —C(O)N(R5-1R5-1a), —S(O)2R5-1, —SO)R5-1, —S(O)2N(R5-1R5-1a), —S(O)N(R5-1R5-1a), —N═C(R5-1R5-1a), hydroxyl, C1˜6 alkyl, phenyl, phenyl with at least one hydrogen substituted by R5-1, C1˜6 alkoxy, —N(R5-1R5-1a), —N(R5-1)C(O)R5-1a, —N(R5-1)C(O)OR5-1a, —N(R5-1)C(O)N(R5-1a R5-1b), —OC(O)R5-1, —OC(O)OR5-1, —OC(O)N(R5-1R5-1a) and —SR5-1, wherein R5-1, R5-1a and R5-1b are each independently hydrogen, C1˜6 alkyl, C2˜6 alkenyl, C2˜6 alkynyl, C1˜6 alkyl with at least one hydrogen substituted by halogen, C2˜6 alkenyl with at least one hydrogen substituted by halogen, or C2˜6 alkynyl with at least one hydrogen substituted by halogen.

### Claim 2 (depends on 1)

The compound or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1, wherein Z is
R1 is hydrogen or C1˜4 alkyl;
R2 is hydrogen, C1˜4 alkyl, three to six-membered cycloalkyl or four to six-membered epoxyalkyl;
R3 is
wherein, R3-1 is hydrogen, hydroxyl, C1˜4 alkyl, C1˜4 alkoxy or —N(R3-2R3-2a),
R3-2 and R3-2a are each independently hydrogen or C1˜4 alkyl,
Ar is phenyl, 5- or 6-membered monocyclic heteroaryl, or a 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R3-3, and the R3-3 is hydrogen, halogen, C1˜4 alkyl, hydroxyl, C1˜4 alkoxy, C1˜4 haloalkyl or —N(R3-3aR3-3b),
R3-3a and R3-3b are each independently hydrogen or C1˜4 alkyl;
R4 is
wherein, R4-1 is phenyl, phenyl with at least one hydrogen atom substituted by R4-11, 5- or 6-membered monocyclic heteroaryl, or 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R4-11, and the R4-11 is hydrogen, halogen, nitro, C1˜4 alkyl, three to six-membered cycloalkyl, C1˜4 alkoxy, —N(R4-1aR4-1b), phenyl, C1˜4 haloalkyl, C1˜4 haloalkoxy or
R4-1a and R4-1b are each independently hydrogen, C1˜4 alkyl or three to six membered cycloalkyl, and R4-1a and R4-1b can be bonded to each other to form a ring,
R4-2 is C1˜4 alkyl, three- to six-membered cycloalkyl, or when R2 is C1˜4 alkyl, R4-2 and R2 are bonded to form a 4˜8 membered ring,
R4-3 is C1˜4 alkyl or C1˜4 alkoxy;
when the number of R5 is not 0, each R5 is independently selected from halogen, nitro, nitrile group, —N+(R5-1)3, C1˜4 haloalkyl, —C(O)OR5-1, —C(O)R5-1, —C(O)N(R5-1R5-1a), —S(O)2R5-1, —S(O)R5-1, —N═C(R5-1R5-1a), hydroxyl, C1˜4 alkyl, phenyl, phenyl with at least one hydrogen substituted by R5-1, C1˜4 alkoxy, —N(R5-1R5-1a), —N(R5-1)C(O)R5-1a and —OC(O)R5-1, wherein R5-1, R5-1a and R5-1b are each independently hydrogen, C1˜4 alkyl, and C1˜4 alkyl with at least one hydrogen substituted by halogen.

### Claim 3 (depends on 1)

The compound or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1, wherein Z is
and/or, R1 is hydrogen;
and/or, R2 is hydrogen, methyl, ethyl, n-propyl, isopropyl,
and/or, R3 is
wherein R3-1 is hydrogen, hydroxyl, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy or isobutoxy,
Ar is phenyl, 5- or 6-membered nitrogen-containing monocyclic heteroaryl;
and/or, R4 is
wherein R4-1 is phenyl, phenyl with at least one hydrogen atom substituted by R4-11, 5- or 6-membered monocyclic heteroaryl, and 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R4-11, 8 to 10-membered fused bicyclic heteroaryl, or 8 to 10-membered fused bicyclic heteroaryl with at least one hydrogen atom substituted by R4-11, and the R4-11 is hydrogen, halogen, nitrogen methyl, ethyl, n-propyl, isopropyl,
fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, chloromethyl, chloroethyl, chloro-n-propyl, chloroisopropyl, bromomethyl, bromoethyl, bromo-n-propyl, bromoisopropyl, iodomethyl, iodoethyl, iodo-n-propyl, iodoisopropyl, fluoromethoxy, fluoroethoxy, fluoro-n-propoxy, fluoroisopropoxy, chloromethoxy, chloroethoxy, chloro-n-propoxy, chloroisopropoxy, bromomethoxy, bromoethoxy, bromo-n-propoxy, bromoisopropoxy, iodooxymethyl, iodoethoxy, iodo-n-propoxy, iodoisopropoxy or
R4-2 is methyl, ethyl, n-propyl or isopropyl, or when R2 is methyl, ethyl or n-propyl, R4-2 and R2 are bonded to form a 4-8 membered ring,
R4-3 is methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy or isopropoxy;
and/or, when the number of R5 is not 0, each is independently selected from halogen, nitro, nitrile, —N+(R5-1)3, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, chloromethyl, chloroethyl, chloron-n-propyl, chloroisopropyl, bromomethyl, bromoethyl, bromon-n-propyl, bromoisopropyl, —C(O)OR5-1, —C(O)R5-1, —C(O)N(R5-1R5-1a), —S(O)2R5-1, —S(O)R5-1, —N═C(R5-1R5-1a), hydroxyl, methyl, ethyl, n-propyl, isopropyl, phenyl, phenyl with at least one hydrogen substituted by R5-1, methoxy, ethoxy, n-propoxy, isopropoxy, —N(R5-1R5-1a), —N(R5-1)C(O)R5-1a and —OC(O)R5-1, wherein R5-1, R5-1a and R5-1b are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, chloromethyl, chloroethyl, chloro-n-propyl, chloroisopropyl, bromomethyl, bromoethyl, bromo-n-propyl or bromoisopropyl.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1, wherein Z is

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1, wherein the compound has a structure represented by Formula (II);
wherein R2 is hydrogen, C1˜4 alkyl, three to six-membered cycloalkyl or four to six-membered epoxyalkyl;
R3 is
wherein R3-1 is hydrogen, hydroxyl, C1˜4 alkyl, C1˜4 alkoxy, three to six-membered cycloalkyl, three to six-membered epoxyalkyl, —N(R3-2R3-2a), —CH2C(O)R3-2, —CH2C(O)OR−2 or —CH2C(O)NR3-2R3-2a,
R3-2 and R3-2a are each independently hydrogen, C1˜4 alkyl or three to six-membered cycloalkyl,
Ar is phenyl, 5- or 6-membered monocyclic heteroaryl, or 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R3-3, and the R3-3 is hydrogen, halogen, C1˜4 alkyl, three to six-membered cycloalkyl, hydroxyl, C1˜4 alkoxy, three to six-membered epoxyalkyl, C1˜4 haloalkyl, C2˜4 alkenyl, C2˜4 alkynyl, —N(R3-3aR3-3b) or phenyl,
R3-3a and R3-3b are each independently hydrogen, C1˜4 alkyl or three to six-membered cycloalkyl;
R4 is
wherein R4-1 is phenyl, phenyl with at least one hydrogen atom substituted by R4-11, 5- or 6-membered monocyclic heteroaryl, and 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R4-11, 8 to 10-membered fused bicyclic heteroaryl, or 8 to 10-membered fused bicyclic heteroaryl with at least one hydrogen atom substituted by R4-11, wherein R4-11 is hydrogen, halogen, nitro, C1˜4 alkyl, three to six-membered cycloalkyl, C1˜4 alkoxy, —N(R4-1aR4-1b), phenyl, C1˜4 haloalkyl, C1˜4 haloalkoxy or
R4-1a and R4-1b are each independently hydrogen, C1˜4 alkyl or three to six-membered cycloalkyl, and R4-1a and R4-1b can be bonded to each other to form a ring,
R4-2 is a C1˜4 alkyl, a three- to six-membered cycloalkyl, or when R2 is a C1˜4 alkyl, R4-2 and R2 are bonded to form a 4 to 8-membered ring,
R4-3 is C1˜4 alkyl or C1˜4 alkoxy;
when the number of R5 is not 0, each is independently selected from halogen, nitro, nitrile, —N+(R5-1)3, C1˜4 haloalkyl, —C(O)OR5-1, —C(O)R5-1, —C(O)N(R5-1R5-1a), —S(O)2R5-1, —S(O)R5-1, —N═C(R5-1R5-1a), hydroxyl, C1˜4 alkyl, phenyl, phenyl with at least one hydrogen substituted by R5-1, C1˜4 alkoxy, —N(R5-1R5-1a), —N(R5-1)C(O)R5-1a, —OC(O)R5-1, —OC(O) N(R5-1R5-1a) and —SR5-1, wherein R5-1, R5-1a and R5-1b are each independently hydrogen, C1˜4 alkyl, C2˜4 alkenyl, C2˜4 alkynyl, C1˜4 alkyl with at least one hydrogen substituted by halogen, 2˜4 alkenyl with at least one hydrogen substituted by halogen, or C2˜4 alkynyl with at least one hydrogen substituted by halogen.

### Claim 6 (depends on 5)

The compound or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 5, wherein when the number of R5 is not 0, each R5 is independently selected from halogen, nitro, nitrile, —N+(R5-1)3, C1˜4 haloalkyl, —C(O)OR5-1, —C(O)R5-1, —C(O)N(R5-1R5-1a), —S(O)2R5-1, —S(O)R5-1 and —N═C(R5-1R5-1a);
wherein R5-1 and R5-1a are each independently hydrogen, C1˜4 alkyl, C2˜4 alkenyl, C2˜4 alkynyl, and C1˜4 alkyl with at least one hydrogen substituted by halogen, C2˜4 alkenyl with at least one hydrogen substituted by halogen or C2˜4 alkynyl group with at least one hydrogen substituted by halogen.

### Claim 7 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1, wherein the compound has a structure represented by Formula (III);
wherein, R2 is hydrogen, C1˜4 alkyl, three to six-membered cycloalkyl or four to six-membered epoxyalkyl;
R3 is
wherein R3-1 is hydrogen, hydroxyl, C1˜4 alkyl, C1˜4 alkoxy, three to six-membered cycloalkyl, three to six-membered epoxyalkyl,
—N(R3-2R3-2a), —CH2C(O)R3-2, —CH2C(O)OR3-2 or —CH2C(O)NR3-2R3-2a,
R3-2 and R3-2a are each independently hydrogen, C1˜4 alkyl or three to six-membered cycloalkyl,
Ar is phenyl, 5- or 6-membered monocyclic heteroaryl, or 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R3-3, and the R3-3 is hydrogen, halogen, C1˜4 alkyl, three to six-membered cycloalkyl, hydroxyl, C1˜4 alkoxy, three to six-membered epoxyalkyl, C1˜4 haloalkyl, C2˜4 alkenyl, C2˜4 alkyne, —N(R3-3aR3-3b) or phenyl,
R3-3a and R3-3b are each independently hydrogen, C1˜4 alkyl or three to six-membered cycloalkyl;
R4 is
wherein R4-1 is phenyl, phenyl with at least one hydrogen atom substituted by R4-11, 5- or 6-membered monocyclic heteroaryl, and 5- or 6-membered monocyclic heteroaryl with at least one hydrogen atom substituted by R4-11, 8 to 10-membered fused bicyclic heteroaryl, or 8 to 10-membered fused bicyclic heteroaryl with at least one hydrogen atom substituted by R4-11, and the R4-11 is hydrogen, halogen, nitro, C1˜4 alkyl, three to six-membered cycloalkyl, C1˜4 alkoxy, —N(R4-1aR4-1b), phenyl, C1˜4 haloalkyl, C1˜4 haloalkoxy or
R4-1a and R4-1b are each independently hydrogen, C1˜4 alkyl or three to six-membered cycloalkyl, and R4-1a and R4-1b can be bonded to each other to form a ring,
R4-2 is C1˜4 alkyl or three- to six-membered cycloalkyl, or when R2 is C1˜4 alkyl, R4-2 and R2 are bonded to form a 4 to 8-membered ring,
R4-3 is C1˜4 alkyl or C1˜4 alkoxy;
when the number of R5 is not 0, each R5 is independently selected from halogen, nitro, nitrile group, —N+(R5-1)3, C1˜4 haloalkyl, —C(O)OR5-1, —C(O)R5-1, —C(O)N(R5-1R5-1a), —S(O)2R5-1, —S(O)R5-1, —N═C(R5-1R5-1a), hydroxyl, C1˜4 alkyl, phenyl, phenyl with at least one hydrogen substituted by R5-1, C1˜4 alkoxy, —N(R5-1R5-1a), —N(R5-1)C(O)R5-1a, —OC(O)R5-1, —OC(O) N(R5-1R5-1a) or —SR5-1, wherein R5-1R5-1a and R5-1b are each independently hydrogen, C1˜4 alkyl, C2˜4 alkenyl, C2˜4 alkynyl, C1˜4 alkyl with at least one hydrogen substituted by halogen, C2˜4 alkenyl with at least one hydrogen substituted by halogen, and C2˜4 alkynyl with at least one hydrogen substituted by halogen.

### Claim 8 (depends on 7)

The compound or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 7, wherein when the number of R5 is not 0, each R5 is independently selected from hydroxyl, C1˜4 alkyl, phenyl, phenyl with at least one hydrogen substituted by R5-1, C1˜4 alkoxy, —N(R5-1R5-1a), —N(R5-1)C(O)R5-1a, —OC(O)R5-1, —OC(O)N(R5-1R5-1a) or —SR5-1, wherein R5-1, R5-1a and R5-1b are each independently hydrogen, C1˜4 alkyl, C2˜4 alkenyl, C2˜4 alkynyl, C1˜4 alkyl with at least one hydrogen substituted by halogen, C2˜4 alkenyl with at least one hydrogen substituted by halogen and C2˜4 alkynyl with at least one hydrogen substituted by halogen.

### Claim 9 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1, wherein the compound is selected from any one of the following compounds:

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1.

### Claim 11 (depends on 1)

A method of inducing mitophagy in a subject, comprising administering to the subject the compound, or the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof of claim 1.

### Claim 12 (depends on 10)

A method of inducing mitophagy in a subject, comprising administering to the subject the pharmaceutical composition of claim 10.
